Human papillomavirus type 16 E7 protein (HPV16 E7)

Human papillomavirus type 16 E7 (HPV16 E7) is a primary viral oncoprotein essential for the development and maintenance of malignancies caused by high-risk HPV infection. Its biological function centers on binding to and inducing the ubiquitin-mediated degradation of the retinoblastoma protein (pRb), which disrupts cell cycle checkpoints and promotes uncontrolled cellular proliferation (UniProt P03129). Because E7 is constitutively expressed in HPV-transformed cells but absent in healthy human tissues, it serves as a highly specific target for therapeutic vaccines and immunotherapies (NCI Thesaurus). The Hsp65–E7 fusion protein (HspE7) is a specific therapeutic approach designed to enhance the immunogenicity of the E7 antigen by fusing it to a heat shock protein carrier from Mycobacterium bovis. This fusion facilitates the uptake of the E7 antigen by dendritic cells, which then process and present E7 epitopes on MHC molecules to activate a robust CD8+ cytotoxic T-lymphocyte response (Chu et al., 2000). By targeting E7-expressing cells, these therapies aim to eliminate pre-cancerous lesions and established HPV-associated tumors (Goldstone et al., 2002).

Other names

HPV-16 E7E7 oncoproteinProtein E7Human papillomavirus type 16 protein E7

Induction of antigen-specific cellular immune response through dendritic cell-mediated cross-presentation of E7 peptides to CD8+ and CD4+ T cells.